Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, MRI-1026, 1275 York Ave, New York, NY 10021, USA.
Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6.
We previously reported a 52% correlation between the primary surgeon's assessment and the postoperative computed tomographic (CT) scan findings of residual disease in patients reported to have undergone cytoreduction to residual disease of 1 cm or smaller. This is a follow-up analysis of survival and prognostic factors for patients who had concordant and discordant postoperative CT scan findings.
Patients scheduled for primary cytoreductive surgery for presumed advanced ovarian carcinoma were offered enrollment in a prospective study evaluating the ability of preoperative CT scan to predict cytoreductive outcome. If cytoreduction to residual disease of 1 cm or smaller was reported, a CT scan was done 7 to 35 days postoperatively. The CT scan findings were graded by protocol radiologists using a qualitative analysis scale from 1 (normal) to 5 (definitely malignant).
From January 2001 to September 2006, 285 patients were enrolled; 67 patients were eligible. Postoperative CT scans confirmed the primary surgeon's assessment of no residual disease larger than 1 cm in 38 cases (57%). In 29 cases (43%), the radiologist found residual disease larger than 1 cm and reported it as probably or definitely malignant. Comparing concordant versus discordant findings, there was no significant difference in median progression-free survival (21 vs 17 months; P = 0.365) or overall survival (60 vs 43 months; P = 0.146). Age (P = 0.040), stage (P = 0.038), and residual disease of 0.5 mm or smaller versus 0.6 to 1.0 cm (P = 0.018) were significant for overall survival on multivariate analysis.
On this follow-up analysis, only age, stage, and residual disease were significant prognostic factors for overall survival. Discordant findings between the primary surgeon's assessment and the postoperative CT scan findings of residual disease was not an independent prognostic factor.
我们曾报道过,在报告接受细胞减灭术至残余肿瘤直径 1cm 或更小的患者中,主刀医生的评估与术后计算机断层扫描(CT)残余疾病发现之间存在 52%的相关性。这是对术后 CT 扫描发现与主刀医生评估结果一致和不一致的患者的生存和预后因素的随访分析。
对计划接受原发性细胞减灭术治疗疑似晚期卵巢癌的患者进行前瞻性研究,评估术前 CT 扫描预测细胞减灭术结果的能力。如果报告肿瘤减灭术至残余肿瘤直径 1cm 或更小,则在术后 7 至 35 天进行 CT 扫描。CT 扫描结果由协议放射科医生使用从 1(正常)到 5(肯定恶性)的定性分析量表进行分级。
从 2001 年 1 月至 2006 年 9 月,共纳入 285 例患者,其中 67 例符合条件。术后 CT 扫描证实 38 例(57%)主刀医生评估的无大于 1cm 的残余肿瘤。在 29 例(43%)中,放射科医生发现大于 1cm 的残余肿瘤,并报告为可能或肯定恶性。比较一致和不一致的发现,无进展生存期的中位数(21 个月 vs 17 个月;P=0.365)或总生存期(60 个月 vs 43 个月;P=0.146)均无显著差异。多因素分析显示,年龄(P=0.040)、分期(P=0.038)和残余肿瘤直径为 0.5mm 或更小与 0.6-1.0cm(P=0.018)对总生存期有显著影响。
在这项随访分析中,只有年龄、分期和残余肿瘤是总生存期的显著预后因素。主刀医生的评估与术后 CT 扫描残余疾病发现不一致不是独立的预后因素。